The Technical Advisory Group of the World Health Organization (WHO) has recommended ‘Listed for Emergency Use’ (EUL) status for Covaxin, an anti-coronavirus COVID-19 vaccine from Bharat Biotech. Sources gave this information.
WHO is evaluating data from clinical trials of Covaxin for the use of the EUL. The technical advisory group had on October 26 sought additional clarifications from the company for conducting a final ‘risk-benefit assessment’ to list the vaccine for emergency use.
A source said, WHO’s technical advisory group has recommended listed status for emergency use for the vaccine. The WHO Technical Advisory Group is an independent advisory group that recommends to the WHO whether an anti-COVID-19 vaccine can be listed for emergency use under the EUL process.
The Covaxin showed 77.8 percent efficacy against symptomatic COVID-19 disease and 65.2 percent protection against the new delta form of the virus. The company said in June that it had finished the final analysis of the effects of Covaccine from Phase III trials.